ESC 2023 – Heart Failure Guideline Review

Published: 01 September 2023

  • Views:

    Views Icon 33805
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating
Register or Login to View PDF

Overview

In this short video series, recorded at ESC 2023 in Amsterdam, Prof Carolyn Lam (National Heart Centre Singapore, SG) and Prof Giuseppe Rosano (St George’s University Medical School of London, UK) discuss the latest heart failure guideline updates and what this means for clinical practice. 

 

Since the publication of the 2021 ESC Guidelines, several randomised controlled trials have provided further insight into optimal patient management. As such, this update of the guidelines – developed by the task force of the European Society of Cardiology (ESC) with contributions from the Heart Failure Association (HFA) of the ESC and released at ESC 2023 – aims to best support the diagnosis and treatment of acute and chronic heart failure.

 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall the main recommendations set out in the ESC guideline update publication
  • Compare the guideline updates to existing full European and American guidelines
  • Identify which clinical data has informed specific updated recommendations
  • State the likely impact of guideline changes to heart failure patients
  • Implement guideline updates to daily practice

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other Allied HCPs

More from this programme

Part 1

Distilling the New ESC Guideline Update

In this first part, Prof Carolyn Lam and Prof Giuseppe Rosano discuss why there was a need for an update of the 2021 guidelines, and consider the changing landscape following EMPEROR-PRESERVED, DELIVER, STRONG-HF and IRONMAN.

Part 2

Assessing the Impact on Practice

In part two, the discussants consider the recommendations for SGLT2 inhibitor use for both heart failure with mildly-reduced ejection fraction and heart failure with preserved ejection fraction to reduce cardiovascular death and heart failure hospitalisation, and the expected impact on clinical practice.

Part 3

The Future of Heart Failure Management

In this final part, the physicians discuss the power of early detection in improving outcomes and stress the need for accessible and efficient diagnostic testing for the prevention of heart failure among high-risk patients.

About the episode

In this first part, Prof Carolyn Lam and Prof Giuseppe Rosano discuss why there was a need for an update of the 2021 guidelines, and consider the changing landscape following EMPEROR-PRESERVED, DELIVER, STRONG-HF and IRONMAN.

Faculty Biographies

Carolyn Lam

Carolyn Lam

Professor and Senior Consultant

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.

View full profile
Giuseppe Rosano

Giuseppe Rosano

Consultant Cardiologist and Professor of Cardiology (Hon)

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.
Mahamuod Caqli
4months
Weldone thanks ❤
Nawal Shawky Consultant Mitry
6months
Really ,it is a very concised and targeted to the point lecture.Summaring the updates in 2023 ESC guidelines in HF
Atwebembire Ronald
7months
Thanks so much professor, would it be good to clinically initiate the GDMT based on clinical diagnosis of Heart Failure especially here in Africa where NTpro BNP , and Echocardiography are not readily available
Rubiea Hendawi
7months
Thanks for this great summary